HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Active, not recruiting · Phase 3 · NCT05338970
Conditions: Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
At a glance
- Research payments reported, 2025
- $538,226
- U.S. investigators named
- 18
- Sites paid
- 19
- Planned or actual enrollment
- 586
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- Patritumab Deruxtecan (drug), Platinum-based chemotherapy (drug)
- Dates
- Started 2022-07-08; completion 2026-12-31
- Results posted
- Not yet
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile. There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggests that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.
From ClinicalTrials.gov, last updated 2026-08-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $538,226 in research payments for this study in 2025 (102 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric S. Schaefer, M.D. Hematology & Oncology · Rogers, AR
- Kathryn A. Gold, MD Medical Oncology · La Jolla, CA
- Paul F. La Porte, M.D., PH.D. Hematology & Oncology · Cerritos, CA
- Jorge J. Nieva, M.D. Hematology & Oncology · Los Angeles, CA
- Aditya Sarvaria, MD Hematology & Oncology · San Diego, CA
- James Y. Shen, M.D. Hematology & Oncology · Arcadia, CA
- Jennifer M. Suga, M.D. Hematology & Oncology · Vallejo, CA
- Fadi Kayali, M.D. Medical Oncology · Sarasota, FL
- Conor E. Steuer, MD Hematology & Oncology · Atlanta, GA
- Jonathan N. Swerdloff, MD Medical Oncology · Nampa, ID
- Julia K. Rotow, MD Medical Oncology · Boston, MA
- Ralph V. Boccia, M.D. Hematology & Oncology · Bethesda, MD
- Jatin K. Desani, MD Hematology & Oncology · Manahaukin, NJ
- Balazs Halmos, MD Hematology & Oncology · Cleveland, OH
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
- Sawsan Rashdan, M.D Medical Oncology · Dallas, TX
- Amin Benyounes, M.D. Medical Oncology · Fairfax, VA
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Regents of the University of California $95,881
- Virginia Cancer Specialists Fairfax $58,896
- Ut Southwestern Med Ctr-Zale Lipshy $55,539
- Kaiser Foundation Hospital - Oakland/richmond, CA $48,269
- Providence Portland Medical Center, OR $39,851
- Highlands Oncology Group $34,798
- Inova Fairfax Hospital, VA $32,750
- American Oncology PArtners of Maryland PA $29,240
- Scripps Mercy Hospital, CA $28,730
- Sarah Cannon Research Institute $26,625
- Biomedical Research Alliance of New York LLC $23,378
- Emory University Hospital, GA $18,222
- University Southern California Keck School of Medicine $13,178
- Toi Clinical Research $8,397
- City of Hope National Medical Ctr $7,573
- University of Arkansas Medical Sciences, AR $5,700
- St Luke's Regional Medical Center, ID $4,450
- Dana-Farber Cancer Institute $3,500
- Hackensack University Medical Center, NJ $3,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.